KEYNOTE-671: Perioperative pembrolizumab improves efficacy outcomes regardless of nodal status in patients with early-stage NSCLC

Lung, Respiratory and Thoracic Cancer

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

ESMO Open

Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S

doi: 10.1016/j.esmoop.2025.105870

CHICAGO 2025

Genitourinary Cancer

NIAGARA: Perioperative durvalumab improves ctDNA clearance and clinical outcomes in patients with MIBC

Breast Cancer

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

Lancet Oncol

Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM

doi: 10.1016/S1470-2045(25)00276-1

WCLC 2025

Lung, Respiratory and Thoracic Cancer

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

Lung, Respiratory and Thoracic Cancer

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Lung Cancer

Vaes RDW, Cortiula F, Lyu S, Hiltermann TJN, Houben R, Degens J, Hendriks LEL, Ruysscher D

doi: 10.1016/j.lungcan.2025.108541

Lung, Respiratory and Thoracic Cancer

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Lung Cancer

Eklund EA, Orgard M, Wallin D, Sayin SI, Fagman H, Isaksson J, Raghavan S, Akyürek LM, Nyman J, Wiel C, Hallqvist A, Sayin VI

doi: 10.1016/j.lungcan.2025.108573

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Lung Cancer (Auckl)

Luo FX, Arter Z, Ou SI, Nagasaka M

doi: 10.2147/LCTT.S520833

SABCS 2025

Breast Cancer

TAXIS (SAKK 23/16): Nodal disease volume, nodal understaging and factors associated with additional nodal disease at ALND in patients with stage II–III breast cancer

Related content

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

NIAGARA: Perioperative durvalumab improves ctDNA clearance and clinical outcomes in patients with MIBC

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

TAXIS (SAKK 23/16): Nodal disease volume, nodal understaging and factors associated with additional nodal disease at ALND in patients with stage II–III breast cancer